24th week of 2021 patent applcation highlights part 28 |
Patent application number | Title | Published |
20210179627 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives - The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain. | 2021-06-17 |
20210179628 | INHIBITING DEUBIQUITINASE USP25 AND USP28 - The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I). | 2021-06-17 |
20210179630 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS - The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R | 2021-06-17 |
20210179631 | Pseudopolymorphic Forms of a HIV Protease Inhibitor - New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. | 2021-06-17 |
20210179632 | THIENOPIPERIDINE DERIVATIVE AND USE THEREOF - The present invention relates to a kind of thienopiperidine derivative or pharmaceutically acceptable acid addition salt thereof and a pharmaceutical composition comprising these compounds, the thienopiperidine derivative related in the present invention has a structure as represented by formula (I): | 2021-06-17 |
20210179633 | KRAS G12C INHIBITORS - The present invention provides compounds of the formula: | 2021-06-17 |
20210179634 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF - The present invention provides a compound represented by Formula (I) or a salt thereof; an LSD1 inhibitor that contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition that contains the compound or a salt thereof; and an antitumor agent that contains the compound or a salt thereof as an active ingredient. | 2021-06-17 |
20210179635 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B - Inhibitors of HBV replication of Formula (I-A) | 2021-06-17 |
20210179636 | ANTIBACTERIAL COMPOUNDS - This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections and in methods of treating bacterial infections. | 2021-06-17 |
20210179637 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS - The invention provides compounds of formula (I): | 2021-06-17 |
20210179638 | Synthesis of Zinc MOF Materials - Method for making a Zn MOF of formula Zn | 2021-06-17 |
20210179639 | PHYSIOLOGICALLY STABLE FLUOROPHORE AND PERFORMING FLUORESCENCE PROBING - A physiologically stable fluorophore includes a terminal moiety including a terminal reactive site that reacts with a reactive group of a substrate; a stability linker covalently bonded to the terminal moiety; and a bridge moiety covalently bonded to the stability linker such that the stability linker is interposed through chemical bonds between the bridge moiety and the terminal moiety; and a fluorescent moiety covalently bonded to the bridge moiety of the redox moiety and including: an electron bandgap mediator that is covalently bonded to the bridge moiety; a coordinate center covalently bonded to the electron bandgap mediator and that forms a Zwitterionic member with an atom in the electron bandgap mediator; and a steric hinder bonded to the electron bandgap mediator to provide steric hindrance for protection of the coordinate center. | 2021-06-17 |
20210179640 | COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF - The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment. | 2021-06-17 |
20210179641 | METHOD FOR THE DEHYDROGENATION OF DICHLOROSILANE - Dichlorosilane and trichlorosilane are dehydrogenated at elevated temperature in the presence of an ammonium or phosphonium salt as a catalyst, and a halogenated hydrocarbon or hydrogen halide. The method may be used to synthesize organochlorosilane. | 2021-06-17 |
20210179642 | TETRAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF - The objectives of the present invention are: to provide a novel tetrazole silane compound, a method for synthesizing the same, and a silane coupling agent containing the tetrazole silane compound as a component; and to provide a surface treatment solution using the tetrazole silane compound, a method for surface treatment, and a method for adhering two different materials. The tetrazole silane compound according to the present invention is a compound represented by chemical formula (I). (In formula (I), X, R, and n are respectively the same as defined in the specification.) | 2021-06-17 |
20210179643 | Ligand Compound, Transition Metal Compound, and Catalyst Composition Comprising the Transition Metal Compound - The present invention relates to a novel ligand compound, a transition metal compound and a catalyst composition comprising the same. The novel ligand compound and the transition metal compound of the present invention may be useful as a catalyst of polymerization reaction for preparing an olefin-based polymer having a low density. | 2021-06-17 |
20210179644 | SECONDARY ALCOHOL PHOSPHATE ESTER - The invention relates to a compound of following formula (I), and also to the addition salts thereof with an organic or mineral base, the solvates such as hydrates and the mixtures thereof; to the use thereof as a surfactant, wetting agent, detergent, emulsifier, dispersant, corrosion inhibitor, plasticizer, sequestering agent, ionic liquid, stabilizer, lubricant, bitumen additive, gelling agent in oils, flotation collector for ores, adjuvant in the manufacture of plastic objects, anti-static agent, additive for fertiliser coverings and for enhanced oil recovery, and also to the compositions comprising at least one compound of formula (I) and/or a salt thereof, alone or as a mixture. | 2021-06-17 |
20210179645 | Method for preparing phosphorus-containing a-aminonitriles - The present invention relates primarily to processes conducted in a continuously operated reactor for preparing particular phosphorus-containing α-aminonitriles of the formulae (Ia) and (Ib) defined hereinafter from corresponding phosphorus-containing cyanohydrin esters and to the use thereof for preparation of glufosinate or of glufosinate salts. The present invention further relates to a process for producing glufosinate/glufosinate salts. | 2021-06-17 |
20210179646 | METHOD FOR TREATMENT OF SENESCENCE-RELATED DISORDERS - The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammation, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia. | 2021-06-17 |
20210179647 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B. | 2021-06-17 |
20210179648 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF - A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. | 2021-06-17 |
20210179649 | ORGANIC METAL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE - Organic metal compounds, and organic light-emitting devices employing the same are provided. The organic metal compound has a chemical structure of Formula (I): | 2021-06-17 |
20210179650 | Iron Bis(Imino) Aryl Catalysts and Methods Thereof - The present disclosure related to iron-containing compounds including a 2,6-diiminoaryl ligand and one or more substituted hydrocarbyl substituents. Catalysts, catalyst systems, and processes of the present disclosure can provide polyolefins with high or low molecular weight, low comonomer content, narrow polydispersity indices, and broad orthogonal composition distribution. The present disclosure provides new and improved iron-containing catalysts with enhanced solubility in hydrophobic (nonpolar) solvents. | 2021-06-17 |
20210179651 | HYPERGOLIC METAL ORGANIC FRAMEWORKS - A hypergolic metal organic framework material for producing a hypergol when combined with an oxidizer, comprising a general structure M1-L-M2, wherein L is an aromatic organic linker comprising one or more unsaturated substituents, and wherein M1 and M2 are same or different metal cations. | 2021-06-17 |
20210179652 | SOLID SOLUTION APPROACH FOR REDOX ACTIVE METAL ORGANIC FRAMEWORKS WITH TUNABLE REDOX CONDUCTIVITY - Various embodiments relate to a method for producing a metal-organic framework (MOF) having a desired redox conductivity and including redox-active linkers, having w-alkyl-ferrocene groups, via de novo solvothermal synthesis. Various embodiments relate to a metal-organic framework (MOF) linker comprising an w-alkyl-ferrocene group. Various embodiments relate to a metal-organic framework (MOF), having a first plurality of redox-active linkers, each having an ω-alkyl-ferrocene group. The MOF according to various embodiments, may further have one or more redox-inactive linkers. Various embodiments relate to materials, apparatuses, and components that include the MOF according to various embodiments. For example, various embodiments relate to thin-films, bulk powders, or electrodes. | 2021-06-17 |
20210179653 | REDOX REVERSIBLE FLUORESCENT PROBE AND PERFORMING SINGLE-ELECTRON TRANSFER FLUORESCENCE PROBING - A redox reversible fluorescent probe for performing single-electron transfer fluorescence probing includes: a redox moiety including: a terminal moiety; an electron transfer metal coordinatively bonded to the terminal moiety; and a bridge moiety coordinatively bonded to the electron transfer metal; and a fluorescent moiety covalently bonded to the bridge moiety of the redox moiety and comprising: an electron bandgap mediator that is covalently bonded to the bridge moiety; a coordinate center covalently bonded to the electron bandgap mediator and that forms a Zwitterionic member with an atom in the electron bandgap mediator; and a steric hinder bonded to the electron bandgap mediator to provide steric hindrance for protection of the coordinate center. | 2021-06-17 |
20210179654 | EFFICIENT METHOD FOR THE PREPARATION OF CANGRELOR - The present invention relates to a process for the preparation of Cangrelor in salt form of formula (V) by preparation and subsequent hydrolysis of an intermediate of formula (IV). The process is characterised by the high yield and purity of the product, and can be used industrially. | 2021-06-17 |
20210179655 | Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease - The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds. | 2021-06-17 |
20210179656 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 2021-06-17 |
20210179657 | CHARGE-TAGGED NUCLEOTIDES AND METHODS OF USE THEREOF - Provided is a method including detecting an incorporation of a labelled nucleotide into a nascent polynucleotide strand complementary to a template polynucleotide strand by a polymerase, wherein the polymerase is tethered to a solid support conductive channel by a tether and the labelled nucleotides is a compound of Formula I: | 2021-06-17 |
20210179658 | ORTHOGONAL PROTECTING GROUPS FOR THE PREPARATION OF STEREODEFINED PHOSPHOROTHIOATE OLIGONUCLEOTIDES - The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers comprising an amine containing chiral auxiliary group, and methods of orthogonally protecting the nitrogen of chiral auxiliaries during oligonucleotide synthesis, preventing post elongation chain cleavage, increasing yield and purity of stereodefined phosphorothioate oligonucleotides. | 2021-06-17 |
20210179659 | ANTISENSE NUCLEIC ACIDS - The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. | 2021-06-17 |
20210179660 | GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER - The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostrate Cancer (CRPC) and/or doubly resistant prostrate cancer, especially in individuals having prostrate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostrate cancer. In some embodiments, GR inhibitors also have Androgen Receptors (AR) inhibitory activity and or administered in conjunction with AR Inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostrate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes. The present invention also provides systems for using such agents, for example to treat and/or reduce risk of CRPC and/or doubly resistant prostrate cancer. | 2021-06-17 |
20210179661 | Intermediates for the Synthesis of Bile Acid Derivatives, in Particular of Obeticholic Acid - The present invention relates to compounds which are intermediates in the synthesis of bile acid derivatives with pharmacological activity. The invention relates to compounds of general formula (I): | 2021-06-17 |
20210179662 | METHOD FOR FRACTIONATING SOLUBLE FRACTIONS OF PEAS, FRACTION THUS OBTAINED AND UPGRADE THEREOF - The invention relates to a method for fractionating soluble fractions of peas, including, in sequence, a step of microfiltering or centrifuging, followed by a step of ultrafiltering, and optionally a reverse-osmosis step. A reduction of the leakage of proteins toward the soluble fractions, an improvement of the yield of the single concentration step by evaporating the soluble fractions, and the selective isolation of proteins of interest are thus achieved. The method is easy to implement, the devices used at each single step are conventional and well known to the person skilled in the art. Also, the method of the invention does not use any organic solvent other than water. | 2021-06-17 |
20210179663 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 2021-06-17 |
20210179664 | Synthetic peptide sp4 and use thereof - A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs. | 2021-06-17 |
20210179665 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF - The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences. | 2021-06-17 |
20210179666 | CYCLIC PEPTIDES AND METHODS OF USE THEREOF - Certain embodiments of the invention provide a cyclic compound of formula I: | 2021-06-17 |
20210179667 | SYNTHESIS OF ECHINOCANDIN ANTIFUNGAL AGENT - The present invention relates to echinocandin cyclopeptides and to methods for preparing echinocandin cyclopeptides. | 2021-06-17 |
20210179668 | NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS - Novel mammalian expressed human immunodeficiency virus envelope Protein antigens Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV. | 2021-06-17 |
20210179669 | HEPATITIS E VIRUS ORF2 CAPSID POLYPEPTIDES AND USES THEREOF - Hepatitis F virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and arc the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection. | 2021-06-17 |
20210179670 | HIV Vaccine Formulation - Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions. | 2021-06-17 |
20210179671 | IMMUNOGLOBULIN-BINDING PROTEIN, AND AFFINITY CARRIER USING SAME - An affinity carrier may have improved alkali resistance. An immunoglobulin-binding protein containing a mutant polypeptide chain, as well as an affinity carrier containing a solid-phase carrier to which the immunoglobulin-binding protein is bound, may be a mutant polypeptide chain having an amino acid sequence having at least 85% identity to an amino acid sequence indicated by any of SEQ ID NO: 1-6 and 57-62, having a predetermined mutation, and having immunoglobulin-binding activity. | 2021-06-17 |
20210179672 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA - Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a | 2021-06-17 |
20210179673 | METHODS AND MATERIALS FOR TREATING CANCER - This document provides methods and materials involved in treating cancer. For example, compositions containing a fusion polypeptide (or a polypeptide conjugate) having a tumor-targeting moiety and a phagocyte engaging moiety as well as methods and materials for using such compositions to treat cancer are provided. | 2021-06-17 |
20210179674 | YEAST WITH IMPROVED ALCOHOL PRODUCTION - Described are compositions and methods relating to yeast cells having a genetic mutation that give rise to increased alcohol production. Such yeast is well-suited for use in alcohol production to reduce fermentation time and/or increase yields. | 2021-06-17 |
20210179675 | SMALL NEAR-INFRARED FLUORESCENT PROTEINS DEVELOPED FROM CYANOBACTERIOCHROME AND METHODS FOR THEIR ENGINEERING - This invention provides the nucleic acid molecules encoding novel small monomeric near-infrared fluorescent protein miRFP670nano, variants and derivatives thereof as well as proteins and peptides encoded by these nucleic acids. The invention also relates to derivatives, homologues, or mutants of the specific proteins referenced above as well as fragments of the nucleic acids and the peptides encoded thereby. The invention further relates to host-cells, stable cell lines and transgenic organisms comprising above-referenced nucleic acid molecules. The present invention also refers to methods of making and using small monomeric near-infrared fluorescent proteins derived from cyanobacteriochromes. The presented protein and its derivatives find use in a variety of applications and approaches, including labeling of biomolecules, cells or cell organelles, detecting protein-protein interactions, and generation of genetically encoded fluorescent biosensors. | 2021-06-17 |
20210179676 | FUSION PROTEIN AND NUCLEIC ACID MOLECULE FOR EXOGENOUS STIMULANT-DEPENDENT STRESS GRANULE ASSEMBLY - A nucleic acid molecule encoding a fusion protein composed of an inducible multimerization moiety at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for exogenous stimulus/G3BP-mediated stress granule formation. Further disclosed are chemical or light inducible multimerization proteins or protein domains that can be used for the nucleic acid molecule production, and a method of inducing stress granule formation in a cell comprising expressing the nucleic acid molecule. | 2021-06-17 |
20210179677 | SODIUM CHANNEL INHIBITORS - Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels. | 2021-06-17 |
20210179678 | FUSION PROTEINS WITH SPECIFICITY FOR ED-B AND LONG SERUM HALF-LIFE FOR DIAGNOSIS OR TREATMENT OF CANCER - The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases. | 2021-06-17 |
20210179679 | SERUM AMYLOID P DERIVATIVES AND THEIR PREPARATION AND USE - One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern. | 2021-06-17 |
20210179680 | POLYPEPTIDE, DERIVATIVES THEREOF, AND APPLICATION THEREOF IN PREPARATION OF DRUGS HAVING RESISTANCE TO PULMONARY FIBROSIS - Provided are a polypeptide specifically binding to TRB3 and application thereof in preparation of drugs for treating and/preventing pulmonary fibrosis. The amino acid sequence of the polypeptide is represented by SEQ ID NO:12 in a sequence list, or two or more amino acids in the amino acid sequence as represented by SEQ ID NO:12 in the sequence list are replaced with unnatural amino acids having side chains that can be linked to each other. The polypeptide and derivatives thereof can specifically bind to TRB3, thereby blocking the interaction between TRB3 and MDM2 proteins. | 2021-06-17 |
20210179681 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY FOR PREVENTING OR TREATING CANCER CONTAINING TUMOR-SPECIFIC DRUG CONJUGATE AND ANTI-PD-L1 ANTIBODY AS ACTIVE INGREDIENTS - The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues. | 2021-06-17 |
20210179682 | CALCIUM-CHELATING PEPTIDES DERIVED FROM EF-HAND CALCIUM-BINDING MOTIF - The disclosure pertains to the field of molecular means capable of binding calcium, in particular peptides which are calcium chelators, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. Polypeptide comprising a first calcium-binding domain, a peptide linker and a second calcium binding domain, wherein the first and second binding domains are linked through the peptide linker, and wherein: the first calcium-binding domain and the second calcium binding domain each comprise at least one calcium-binding site derived from a EF-hand motif; and, the first calcium-binding domain and the second calcium binding domain differ in at least one calcium-binding site. | 2021-06-17 |
20210179683 | METHOD OF RESPONSE PREDICTION FOR BCL2 FAMILY PROTEIN TARGETING DRUG - Provided are a method for prediction of a response to a BCL2 family protein-targeting drug and a method for selection of a subject suitable for treatment with a BCL2 family protein-targeting drug. | 2021-06-17 |
20210179684 | NEUROTROPHIN MUTANTS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - Disclosed herein are compositions and methods for the treatment of non-otic diseases or conditions with Trk receptor agonist compositions and formulations. | 2021-06-17 |
20210179685 | NOVEL INSULIN ANALOGUES AND USES THEREOF - The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes. | 2021-06-17 |
20210179686 | CELL SORTING SYSTEMS AND METHODS OF USE - The presently disclosed subject matter provides methods and systems for isolating cells expressing specific constructs. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and a soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide. | 2021-06-17 |
20210179687 | TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER - The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment. | 2021-06-17 |
20210179688 | HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF - The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V | 2021-06-17 |
20210179689 | COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS - The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of T-cell immunoglobulin mucin receptor 3 (TIM-3) and an extracellular domain of CD40 Ligand (CD40L) or an extracellular domain of OX40 Ligand (OX40L) that find use in the treatment of disease, such as cancer. | 2021-06-17 |
20210179690 | CTLA4-IG FUSION PROTEIN FORMULATION - The present invention discloses a stable pharmaceutical formulation of a fusion protein, wherein the formulation contains buffer, sugar alcohol/polyol, amino acid and surfactant, and wherein the formulation is devoid of sucrose. Additionally, the formulation may also be devoid of a salt. The disclosed fusion protein formulations are liquid formulations that are also suitable for lyophilization. | 2021-06-17 |
20210179691 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-06-17 |
20210179692 | G PROTEIN-COUPLED RECEPTOR (GPCR) LIGAND ASSAY - The systems and methods described herein include the use of Giant Plasma Membrane Vesicles (GPMVs) derived from cells expressing SPASM sensors (e.g., SPASM GPCR sensors). Herein provided are giant plasma membrane vesicle (GPMV) M sensors containing a membrane-associated polypeptide, where the membrane-associated polypeptide contains a target G protein-coupled receptor (GPCR), a linker including an amino acid sequence flanked by a FRET donor and a FRET acceptor, and a receptor partner for the target GPCR, where the linker separates the target GPCR from the receptor partner. In another aspect, provided is a method for quantifying the intrinsic efficacy of a compound for a target GPCR. In another aspect, provided is a method for identifying a compound that interacts with a target GPCR. | 2021-06-17 |
20210179693 | Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE - The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life. | 2021-06-17 |
20210179694 | Antibody Preparations - An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses. | 2021-06-17 |
20210179695 | NOVEL FUNGAL TOXINS AND METHODS RELATED TO THE SAME - Presented herein, in certain aspects, are compositions that comprise novel toxin proteins, the nucleic acids that encode them, and/or portions thereof, which toxins are expressed by fungi of the Mucorales order and are thought to contribute to the pathogenesis of Mucormycosis. Also presented herein, in certain aspects, are methods of detecting the presence or absence of novel fungal toxins and/or the nucleic adds that encode them in a sample, which methods can be used to identify the presence of Mucorales in a subject. Methods and/or compositions presented herein can be used to prevent and/or treat a Mucorales infection. | 2021-06-17 |
20210179696 | Anti-PHF-Tau Antibodies and Uses Thereof - Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. | 2021-06-17 |
20210179697 | IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES - Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical. | 2021-06-17 |
20210179698 | ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF - The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies. | 2021-06-17 |
20210179699 | TREATMENT OF TAUOPATHIES - The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau. | 2021-06-17 |
20210179700 | MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE - Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature. | 2021-06-17 |
20210179701 | METHODS AND COMPOSITIONS FOR PDGF-CC INHIBITION - The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway. | 2021-06-17 |
20210179702 | METHOD OF TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) - The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods. | 2021-06-17 |
20210179703 | Method of Treating Psoriasis with Anti-IL23 Specific Antibody - A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment. | 2021-06-17 |
20210179704 | TREATMENT OF HIDRADENITIS SUPPURATIVA - Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 2021-06-17 |
20210179705 | METHODS OF TREATING AUTO-INFLAMMATORY SYNDROMES USING IL-1BETA ANTIBODIES - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2021-06-17 |
20210179706 | ANTI-IL-1beta ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME - The present invention belongs to the field of immunology, and relates to an anti-IL-1β antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1β antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1β, block the binding of IL-1β to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1β; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors. | 2021-06-17 |
20210179707 | BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4 - The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof. | 2021-06-17 |
20210179708 | TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT - This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy. | 2021-06-17 |
20210179709 | ANTI-CAR COMPOSITIONS AND METHODS - The invention provides compositions and methods for treating conditions or diseases associated with expression of a target chimeric antigen receptor (CAR) as described herein. The invention also relates to an anti-target CAR specific to the target CAR as described herein, vectors encoding the same, and recombinant T cells comprising the anti-target CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing an anti-target CAR as described herein. | 2021-06-17 |
20210179710 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY - Methods for treating a proliferative disease by administering a synergistic combination of an antibody against an epitope of CD33 (anti-CD33) and a combination of two or more individual chemotherapeutic agents is disclosed. The combination of chemotherapeutic agents may include cladribine, cytarabine, mitoxantrone, and filgrastim (CLAG-M), and the anti-CD33 may be a humanized monoclonal antibody against CD33 such as HuM195 conjugated with a radionuclide such as | 2021-06-17 |
20210179711 | CD47 BINDING AGENTS - Provided herein are antibody molecules that bind specifically to CD47 and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules. | 2021-06-17 |
20210179712 | COMPOSITIONS AND METHODS FOR USING THE CD2-BASED SIGNALING PATHWAYS TO BLOCK HIV INFECTION - The present disclosure relates to composition and methodology for using the CD2 receptor to block viral replication, such as HIV-1 infection. In one embodiment, viral target cells such as blood CD4 T cells can be rendered resistant to HIV through stimulation of the CD2 receptor with either an antibody, a ligand, or a small molecule that binds to the CD2 receptor. Pre-stimulation of CD2 can be used to enhance the anti-HIV immunity and used to promote immune response from HIV infection or from an anti-HIV vaccine. | 2021-06-17 |
20210179713 | ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF - The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2021-06-17 |
20210179714 | Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells - Increases in CD4 | 2021-06-17 |
20210179715 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE - Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same. | 2021-06-17 |
20210179716 | Antibodies Specific for CD47, PD-L1, and Uses Thereof - Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods. | 2021-06-17 |
20210179717 | ANTIBODIES AGAINST MAC-1 - The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which
| 2021-06-17 |
20210179718 | COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION - The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy. | 2021-06-17 |
20210179719 | Antibody Binding To Tie2 And Use Thereof - The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof. | 2021-06-17 |
20210179720 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF - Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer. | 2021-06-17 |
20210179721 | METHOD OF TREATING OR PREVENTING ISCHEMIA-REPERFUSION INJURY - The present disclosure relates to a method for preventing or treating ischemia-reperfusion injury in a subject the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation. In some examples, the compound is an antibody. | 2021-06-17 |
20210179722 | HUMAN CGRP RECEPTOR BINDING PROTEINS - Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches. | 2021-06-17 |
20210179723 | HUMAN CGRP RECEPTOR BINDING PROTEINS - Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches. | 2021-06-17 |
20210179724 | VARIANT NUCLEIC ACID LIBRARIES FOR ADENOSINE RECEPTORS - Provided herein are methods and compositions relating to adenosine A | 2021-06-17 |
20210179725 | LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT - Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder. | 2021-06-17 |
20210179726 | ANTI-CD27 ANTIBODIES AND USE THEREOF - The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a K | 2021-06-17 |
20210179727 | ANTI-CD40 ANTIBODIES AND USES THEREOF - Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders. | 2021-06-17 |